There were 2,007 press releases posted in the last 24 hours and 455,267 in the last 365 days.

Summit Therapeutics to Host R&D Day 11 October 2017

OXFORD, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), will host an R&D Day featuring presentations from experts in quantitative muscle image analysis and CDI alongside Summit’s management on 11 October 2017 in New York City.

This event is open to analysts, institutional investors and members of the press. For more information, email investors@summitplc.com.

A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)
      Tel: +44 (0)1235 443 951
       +1 617 225 4455
     
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson
 
Tel: +44 (0)20 7213 0880
     
N+1 Singer
(Broker)
Aubrey Powell / Lauren Kettle   
  Tel: +44 (0)20 7496 3000
     
MacDougall Biomedical Communications
(US media contact)
Karen Sharma
  Tel: +1 781 235 3060
ksharma@macbiocom.com
     
Consilium Strategic Communications
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville
  Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.